Find your next paid study

Jose Pablo LeoneNCT05501704

Observational

Bone Marrow Aspirate Concentrate vs Corticosteroid Injection for Symptomatic Osteoarthritis (OA) of the Knee: A Randomized Controlled Trial

Prospective single-masked (study participant will be masked), randomized controlled trial to examine the influence of BMAC on patient-reported outcomes (PROs) …

Osteoarthritis of the Knee

Rush University Medical CenterNCT05985785

~$10 – $6,250

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event

The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with plac…

Cardiovascular Disease

Breast Cancer, Quality of LifeBreast Cancer, MetastaticBreast Cancer, Metastatic Breast Cancer+2 more

AstraZenecaNCT07000357

Prospective Evaluation of Quality of Life in Patients With Breast Cancer Brain Metastases and Leptomeningeal Disease

Central nervous system (CNS) metastases including breast cancer brain metastases (BCBMs) and leptomeningeal disease (LMD) are common affecting up to 30% of pat…

University of California, San FranciscoNCT07659652

~$10 – $675

Phase 1

A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4954 Following Single and Multiple Ascending Dose Administration to Healthy Participants With or Without Elevated Lp(a) Levels, and Participants With Dyslipidemia

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZ…

Healthy ParticipantsDyslipidemia

Breast CancerHER2-positive

AstraZenecaNCT06980428

Phase 2

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

This is a Phase 2, single-site, single-arm open-label trial of zanidatamab in patients with early stage, low risk HER2+ BC. The primary objective is to determ…

M.D. Anderson Cancer CenterNCT05035836

~$10 – $6,250

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refr…

BeOne MedicinesNCT06943872

Phase 1

A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC Targeting CD37, for Hematological Malignancies

This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in partic…

Hematological MalignanciesB-cell Non-Hodgkin Lymphoma

Daiichi SankyoNCT07220616

Observational

Sleep as a Mediator of Pain Relief Following Massage Therapy for Chronic Pain: Pilot and Efficacy Study

This study evaluates whether a 6-week semi-standardized integrative therapeutic massage intervention improves sleep quality and pain outcomes compared with usu…

Chronic Musculoskeletal PainSleep Disturbances

Defense and Veterans Center for Integrative Pain ManagementNCT07783139

~$10 – $5,625

A Multicenter, Prospective, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of Venous Leg Ulcers (VALUE)

The main objective of this study is: To assess the efficacy and safety of EscharEx (EX-03 5% formulation) compared to placebo control,in debridement and wound…

Venous Leg Ulcer (VLU)

ICU DeliriumCritical Illness

~$10 – $8,750

MediWound LtdNCT06568627

Phase 2

Exogenous Ketone Ester Supplementation in ICU Delirium (KETONES ICU)

Delirium is a common syndrome in intensive care unit (ICU) patients. Those experiencing delirium may suddenly feel confused, have trouble thinking clearly, str…

Vanderbilt University Medical CenterNCT07364162

~$10 – $6,250

Non-Small Cell Lung Cancer

A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer

The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanc…